These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10191120)

  • 21. Farnesylation of Batten disease CLN3 protein.
    Pullarkat RK; Morris GN
    Neuropediatrics; 1997 Feb; 28(1):42-4. PubMed ID: 9151320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene symbol: CLN3. Disease: juvenile neuronal ceroid lipofuscinosis (Batten disease).
    Leman AR; Pearce DA; Rothberg PG
    Hum Genet; 2005 Feb; 116(3):236. PubMed ID: 15818814
    [No Abstract]   [Full Text] [Related]  

  • 23. Gene symbol: CLN3. Disease: Juvenile neuronal ceroid lipofuscinosis (Batten disease).
    Leman AR; Pearce DA; Rothberg PG
    Hum Genet; 2005 May; 116(6):544. PubMed ID: 15991331
    [No Abstract]   [Full Text] [Related]  

  • 24. Tissue expression and subcellular localization of CLN3, the Batten disease protein.
    Margraf LR; Boriack RL; Routheut AA; Cuppen I; Alhilali L; Bennett CJ; Bennett MJ
    Mol Genet Metab; 1999 Apr; 66(4):283-9. PubMed ID: 10191116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deletion of btn1, an orthologue of CLN3, increases glycolysis and perturbs amino acid metabolism in the fission yeast model of Batten disease.
    Pears MR; Codlin S; Haines RL; White IJ; Mortishire-Smith RJ; Mole SE; Griffin JL
    Mol Biosyst; 2010 Jun; 6(6):1093-102. PubMed ID: 20485751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered gene expression in the eye of a mouse model for batten disease.
    Chattopadhyay S; Kingsley E; Serour A; Curran TM; Brooks AI; Pearce DA
    Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2893-905. PubMed ID: 15326100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A disrupted homologue of the human CLN3 or juvenile neuronal ceroid lipofuscinosis gene in Saccharomyces cerevisiae: a model to study Batten disease.
    Guo WX; Mao C; Obeid LM; Boustany RM
    Cell Mol Neurobiol; 1999 Oct; 19(5):671-80. PubMed ID: 10384264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. pH-dependent localization of Btn1p in the yeast model for Batten disease.
    Wolfe DM; Padilla-Lopez S; Vitiello SP; Pearce DA
    Dis Model Mech; 2011 Jan; 4(1):120-5. PubMed ID: 20959629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A yeast model for classical juvenile Batten disease (CLN3).
    Barwell KJ; Broom MF
    Eur J Paediatr Neurol; 2001; 5 Suppl A():127-9. PubMed ID: 11588983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A murine model for juvenile NCL: gene targeting of mouse Cln3.
    Greene ND; Bernard DL; Taschner PE; Lake BD; de Vos N; Breuning MH; Gardiner RM; Mole SE; Nussbaum RL; Mitchison HM
    Mol Genet Metab; 1999 Apr; 66(4):309-13. PubMed ID: 10191119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moving towards therapies for juvenile Batten disease?
    Cooper JD
    Exp Neurol; 2008 Jun; 211(2):329-31. PubMed ID: 18400221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isolation and chromosomal mapping of a mouse homolog of the Batten disease gene CLN3.
    Lee RL; Johnson KR; Lerner TJ
    Genomics; 1996 Aug; 35(3):617-9. PubMed ID: 8812504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease.
    Chan CH; Ramirez-Montealegre D; Pearce DA
    Neuropathol Appl Neurobiol; 2009 Apr; 35(2):189-207. PubMed ID: 19284480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression studies of CLN3 protein.
    Kaczmarski W; Kida E; Lach A; Rubenstein R; Zhong N; Wisniewski KE
    Neuropediatrics; 1997 Feb; 28(1):33-6. PubMed ID: 9151318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitric oxide signaling is disrupted in the yeast model for Batten disease.
    Osório NS; Carvalho A; Almeida AJ; Padilla-Lopez S; Leão C; Laranjinha J; Ludovico P; Pearce DA; Rodrigues F
    Mol Biol Cell; 2007 Jul; 18(7):2755-67. PubMed ID: 17475770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A model for Batten disease protein CLN3: functional implications from homology and mutations.
    Janes RW; Munroe PB; Mitchison HM; Gardiner RM; Mole SE; Wallace BA
    FEBS Lett; 1996 Dec; 399(1-2):75-7. PubMed ID: 8980123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction between Sdo1p and Btn1p in the Saccharomyces cerevisiae model for Batten disease.
    Vitiello SP; Benedict JW; Padilla-Lopez S; Pearce DA
    Hum Mol Genet; 2010 Mar; 19(5):931-42. PubMed ID: 20015955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Juvenile neuronal ceroid lipofuscinosis (Batten disease) CLN3 mutation (Chrom 16p11.2) with different phenotypes in a sibling pair and low intensity in vivo autofluorescence.
    Mantel I; Brantley MA; Bellmann C; Robson AG; Holder GE; Taylor A; Anderson G; Moore AT
    Klin Monbl Augenheilkd; 2004 May; 221(5):427-30. PubMed ID: 15162299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Over-expression of CLN3P, the Batten disease protein, inhibits PANDER-induced apoptosis in neuroblastoma cells: further evidence that CLN3P has anti-apoptotic properties.
    Narayan SB; Rakheja D; Pastor JV; Rosenblatt K; Greene SR; Yang J; Wolf BA; Bennett MJ
    Mol Genet Metab; 2006 Jun; 88(2):178-83. PubMed ID: 16515873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected].
    Mitchison HM; Bernard DJ; Greene ND; Cooper JD; Junaid MA; Pullarkat RK; de Vos N; Breuning MH; Owens JW; Mobley WC; Gardiner RM; Lake BD; Taschner PE; Nussbaum RL
    Neurobiol Dis; 1999 Oct; 6(5):321-34. PubMed ID: 10527801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.